FY27 Revenue Growth: Early-to-Mid Teens
Management expects revenue growth of 13-15% in FY27, driven by network maturation, sustained Delhi NCR growth, and Suburban recovery.
DRLALPATHLABS / guidance tracker
Keep management guidance in view.
Dr Lal Path · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY27 EBITDA Margin: 27-28%
EBITDA margin expected to remain in 27-28% range as investments in labs, R&D, and infrastructure continue.
FY27 Capex: ₹100-120 crore
Capital expenditure planned for 12-15 new labs, precision lab setup, and one or two radiology centers.